- As the stock sells-off on this morning's FDA news, Summer Street is out with some commentary on Amarin (AMRN -10.3%).
- "We believe that AMRN has almost no chance of getting the FDA to approve Vascepa for treating moderate triglycerides without outcomes data," Bart Classen says.
- "A positive outcome trial is a long shot because no agent has ever shown an outcome benefit over statins." the analyst adds for good measure.
Summer Street talks Amarin, Vascepa amid sell-off
Nov 22 2013, 14:18 ET